Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Novacyt
  6. News
  7. Summary
    ALNOV   FR0010397232

NOVACYT

(ALNOV)
  Report
Real-time Quote. Real-time Euronext Paris - 10/19 11:35:11 am
3.03 EUR   +1.00%
10/16NOVACYT : 2021 agm
PU
10/01NOVACYT : Convening notice for 18th October 2021
PU
09/30NOVACYT : Launches Two New PCR Tests for COVID-19, Other Winter Viruses
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Novacyt : Proposed accounting treatment of ongoing DHSC dispute in 2021 interim results

09/16/2021 | 02:22am EDT

Paris, France and Camberley, UK - 16 September 2021 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the proposed accounting treatment of the ongoing DHSC dispute on its unaudited H1 2021 interim results for the six months ended 30 June 2021. The interim results are expected to be announced on 27 September 2021.

http://novacyt.com/wp-content/uploads/2021/09/Proposed-accounting-treatment-of-ongoing-DHSC-dispute-in-2021-interim-results-16.09-21.pdf

Disclaimer

Novacyt SA published this content on 16 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 September 2021 06:21:03 UTC.


© Publicnow 2021
All news about NOVACYT
10/16NOVACYT : 2021 agm
PU
10/01NOVACYT : Convening notice for 18th October 2021
PU
09/30NOVACYT : Launches Two New PCR Tests for COVID-19, Other Winter Viruses
MT
09/30NOVACYT : R&D update
PU
09/30NOVACYT S.A.(ENXTPA : ALNOV) dropped from Next Biotech Index
CI
09/29NOVACYT : Notice of AGM
PU
09/28NOVACYT : Notice of rescheduled AGM
PU
09/27NOVACYT : 2021 agm
PU
09/27GLOBAL MARKETS LIVE : Intel, Apple, Rolls-Royce, Raytheon, MGM...
09/27NOVACYT : Interim Accounts June 2021
PU
More news
Financials
Sales 2021 112 M 130 M 130 M
Net income 2021 70,0 M 81,4 M 81,4 M
Net cash 2021 90,4 M 105 M 105 M
P/E ratio 2021 3,45x
Yield 2021 -
Capitalization 212 M 246 M 246 M
EV / Sales 2021 1,09x
EV / Sales 2022 0,25x
Nbr of Employees 174
Free-Float 99,4%
Chart NOVACYT
Duration : Period :
Novacyt Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVACYT
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus SELL
Number of Analysts 1
Last Close Price 3,00 €
Average target price 4,10 €
Spread / Average Target 36,7%
EPS Revisions
Managers and Directors
Graham David Mullis Chief Executive Officer & Executive Director
James Martin Mccarthy Chief Financial Officer & Director
James Christopher Wakefield Chairman
Reginald A. Trevor Chief Technology Officer
Lisa Henriet Director-Group Operations
Sector and Competitors
1st jan.Capi. (M$)
NOVACYT-69.39%246
MODERNA, INC.220.51%135 157
GILEAD SCIENCES, INC.13.11%82 626
WUXI APPTEC CO., LTD.29.16%65 873
BIONTECH SE220.28%63 059
LONZA GROUP AG27.29%58 232